Single-cell analysis reveals cellular reprogramming in advanced colon cancer following FOLFOX-bevacizumab treatment
Frontiers in Oncology · 28.07.2023 · 13
DOI: 10.3389/fonc.2023.1219642 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Oncology, online erschienen am 28.07.2023. Verfasst von Meiling Yang und 5 weiteren Autor:innen. Beteiligte Einrichtung: Guangdong Cardiovascular Institute, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou, China. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Introduction
The combination of FOLFOX and bevacizumab (FOLFOX-Bev) is a promising treatment for advanced colorectal cancer (CRC). However, the response of the tumor microenvironment to FOLFOX-Bev is still largely unexplored.
Methods
We conducted single-cell transcriptomic analysis of CRC samples derived from a patient before and after treatment to gain insights into the cellular changes associated with FOLFOX-Bev treatment.
Results
We found that cancer cells with high proliferative, metastatic, and pro-angiogenic properties respond better to FOLFOX-Bev treatment. Moreover, FOLFOX-Bev enhances CD8 + T cell cytotoxicity, thereby boosting the anti-tumor immune response. Conversely, FOLFOX-Bev impairs the functionality of tumor-associated macrophages, plasma cells, and cancer-associated fibroblasts, leading to a decrease in VEGFB-mediated angiogenesis. Furthermore, FOLFOX-Bev treatment reset intercellular communication, which could potentially affect the function of non-cancer cells.
Discussion
Our findings provide valuable insights into the molecular mechanisms underlying the response of advanced CRC to FOLFOX-Bev treatment and highlight potential targets for improving the efficacy of this treatment strategy.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Guangdong Cardiovascular Institute, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou, China.
- Medical Research Institute, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, China.
- Department of Breast Cancer, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, China.
- Medical Oncology, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, China.
- Guangdong Provincial Institute of Geriatrics, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, China.
- Key Laboratory of Stem Cells and Tissue Engineering (Sun Yat-Sen University), Ministry of Education, Guangzhou, China.
Zitieren
APA
Yang, M., Yang, C., Ma, D., Li, Z., Zhao, W., & Yang, D. (2023). Single-cell analysis reveals cellular reprogramming in advanced colon cancer following FOLFOX-bevacizumab treatment. Frontiers in Oncology, 13. https://doi.org/10.3389/fonc.2023.1219642
Vancouver
Yang M, Yang C, Ma D, Li Z, Zhao W, Yang D. Single-cell analysis reveals cellular reprogramming in advanced colon cancer following FOLFOX-bevacizumab treatment. Frontiers in Oncology. 2023;13. doi:10.3389/fonc.2023.1219642
BibTeX
@article{Yang2023,
author = {Yang, Meiling and Yang, Ciqiu and Ma, Dong and Li, Zijun and Zhao, Wei and Yang, Dongyang},
title = {Single-cell analysis reveals cellular reprogramming in advanced colon cancer following FOLFOX-bevacizumab treatment},
journal = {Frontiers in Oncology},
year = {2023},
volume = {13},
doi = {10.3389/fonc.2023.1219642}
}
EUVIMED